Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Sponsor: Novartis Pharmaceuticals
Summary
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.
Official title: A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer
Key Details
Gender
MALE
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
700
Start Date
2023-08-14
Completion Date
2033-07-21
Last Updated
2025-04-24
Healthy Volunteers
No
Conditions
Interventions
AAA617
Long-term follow-up (LTFU) safety study of adult participants with prostate cancer that have received at least one dose of AAA617 from parent interventional Novartis sponsored clinical trials.
Locations (54)
Mayo Clinic Arizona
Scottsdale, Arizona, United States
St. Joseph Hospital
Orange, California, United States
Providence Saint Johns Health Ctr
Santa Monica, California, United States
University of Colorado
Aurora, Colorado, United States
Hartford Hospital
Hartford, Connecticut, United States
VA Medical Center
Washington D.C., District of Columbia, United States
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
University Cancer and Blood Center LLC
Athens, Georgia, United States
Parkview Research Center
Fort Wayne, Indiana, United States
Tulane Cancer Center
New Orleans, Louisiana, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Corewell Health William Beaum Hosp
Royal Oak, Michigan, United States
Mayo Clinic Rochester
Rochester, Minnesota, United States
University of Mississippi Med Ctr
Jackson, Mississippi, United States
Wash U School of Medicine
St Louis, Missouri, United States
Urology Cancer Center PC
Omaha, Nebraska, United States
Nebraska Cancer Specialists
Omaha, Nebraska, United States
Montefiore Medical Center
The Bronx, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Univ of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Univ of Texas Southwest Med Center
Dallas, Texas, United States
UT Health Science Center
Houston, Texas, United States
Onco Hemato Asso of SE Virginia
Roanoke, Virginia, United States
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Olomouc, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Rostock, Germany
Novartis Investigative Site
Delft, Netherlands
Novartis Investigative Site
Maastricht, Netherlands
Novartis Investigative Site
Nijmegen, Netherlands
Novartis Investigative Site
Sabadell, Barcelona, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
L'Hospitalet de Llobregat, Catalonia, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Valencia, Spain
Novartis Investigative Site
Gothenburg, Sweden
Novartis Investigative Site
Stockholm, Sweden
Novartis Investigative Site
Sutton, Surrey, United Kingdom
Novartis Investigative Site
Barnet, United Kingdom
Novartis Investigative Site
Cambridge, United Kingdom
Novartis Investigative Site
Glasgow, United Kingdom
Novartis Investigative Site
Middlesbrough, United Kingdom